DAPARYL L 10/5 10'S

About

DAPARYL L 10/5 combines Dapagliflozin (10mg) and Linagliptin (5mg), providing a complementary approach to managing type 2 diabetes mellitus. Dapagliflozin is an SGLT2 inhibitor that promotes glucose excretion via the kidneys, leading to reduced blood glucose levels, weight loss, and blood pressure reduction. Linagliptin is a DPP-4 inhibitor that increases the levels of incretin hormones, enhancing glucose-dependent insulin secretion and suppressing glucagon release, thereby improving glycemic control with a low risk of hypoglycemia.

This combination targets different pathophysiological mechanisms of diabetes, offering comprehensive blood sugar management. It is suitable for patients who require additional glycemic control beyond what can be achieved with a single agent, and it also provides cardiovascular and renal benefits associated with dapagliflozin, making it a robust option for diabetes care.

Uses

• Management of type 2 diabetes mellitus
• Improved glycemic control
• Adjunct to diet and exercise
• When monotherapy is insufficient

Directions For Use

Take orally once daily, with or without food, as prescribed by your doctor.

Benefits

• Comprehensive blood sugar control
• Low risk of hypoglycemia (due to linagliptin)
• Promotes modest weight loss (due to dapagliflozin)
• Reduces blood pressure
• Offers cardiovascular protection
• Provides renal protective effects

Side Effects

• Urinary tract infections (UTIs)
• Genital yeast infections
• Increased urination
• Thirst
• Dizziness
• Low blood pressure (hypotension)
• Nasopharyngitis
• Cough
• Headache
• Joint pain
• Pancreatitis (rare)
• Bullous pemphigoid (rare)

Safety Measures

• Alcohol - Use with caution, as alcohol can increase the risk of dehydration and may affect blood sugar levels.
• Pregnancy - Not recommended during pregnancy. Consult your doctor for alternative treatments.
• Breastfeeding - Not recommended during breastfeeding as both components may pass into breast milk. Consult your doctor.
• Liver - Use with caution in patients with severe hepatic impairment for dapagliflozin. Linagliptin does not require dose adjustment in liver impairment.
• Kidney - Dapagliflozin is contraindicated in severe renal impairment (eGFR < 30 mL/min/1.73m²). Linagliptin does not require dose adjustment in renal impairment.
• Lung - No direct lung effects. However, monitor for signs of pancreatitis (e.g., severe abdominal pain radiating to the back) which can sometimes present with respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.